Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Amundi

Amundi lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 45.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,042 shares of the medical research company's stock after selling 16,596 shares during the quarter. Amundi owned 0.07% of Bio-Rad Laboratories worth $6,902,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BIO. Larson Financial Group LLC lifted its holdings in shares of Bio-Rad Laboratories by 11.6% in the fourth quarter. Larson Financial Group LLC now owns 1,143 shares of the medical research company's stock worth $375,000 after buying an additional 119 shares in the last quarter. Candriam S.C.A. raised its stake in shares of Bio-Rad Laboratories by 7.0% in the fourth quarter. Candriam S.C.A. now owns 33,747 shares of the medical research company's stock valued at $11,086,000 after acquiring an additional 2,220 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth about $5,119,000. Proficio Capital Partners LLC bought a new position in Bio-Rad Laboratories during the 4th quarter valued at about $9,820,000. Finally, M&T Bank Corp lifted its stake in Bio-Rad Laboratories by 10.1% in the fourth quarter. M&T Bank Corp now owns 2,179 shares of the medical research company's stock worth $716,000 after purchasing an additional 200 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company decreased their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $395.20.

Remove Ads

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded down $6.54 during trading hours on Wednesday, hitting $253.49. 282,789 shares of the stock traded hands, compared to its average volume of 264,458. Bio-Rad Laboratories, Inc. has a 1 year low of $244.00 and a 1 year high of $387.99. The stock has a market capitalization of $7.10 billion, a price-to-earnings ratio of -3.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The firm's 50 day moving average price is $308.56 and its 200-day moving average price is $326.91.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.